Dublin, March 14, 2025 (GLOBE NEWSWIRE) -- The "Dental Burs Market Size, Share & Trends Analysis Report by Material (Diamond Burs, Stainless Steel, Carbide), Application (Oral Surgery, Implantology, Orthodontics), End-Use (Hospitals, Dental Clinics), and Region with Growth Forecasts, 2025-2030" report has been added to ResearchAndMarkets.com's offering.The Dental Burs Market was valued at USD 640.1 million in 2024, and is projected to reach USD 881.6 million by 2030, rising at a CAGR of 5.50%. The increasi ...

A month has gone by since the last earnings report for Envista (NVST) . Shares have lost about 18.2% in that time frame, underperforming the S&P 500.Will the recent negative trend continue leading up to its next earnings release, or is Envista due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important catalysts. NVST Q4 Earnings and Revenues Beat, Operating Margin Cras ...

BREA, Calif., Feb. 25, 2025 /PRNewswire/ -- Envista Holdings Corporation (NYSE: NVST) ("Envista") proudly announced that in 2024, the Envista Smile Project (Smile Project) contributed $1.8 million to further its mission of enhancing oral health accessibility for underserved communities. Since its inception in 2021, the Envista Smile Project has delivered over $4.2 million in dental goods and services, positively impacting approximately 32,000 individuals worldwide. In 2024, the Envista Smile Project: Suppl ...

Distribution and Sales - In 2024, approximately 42% of the company's products were distributed through third-party distributors[51]. - Henry Schein, Inc. accounted for about 10% of the company's sales in both 2024 and 2023, and 11% in 2022[52]. - Sales decreased by 2.2% for the year ended December 31, 2024, with core sales down 1.5% compared to 2023, impacted by foreign currency exchange rates reducing sales by 0.7%[264]. - Total sales for 2024 were $2,510.6 million, a decrease of 2.2% compared to $2,566.5 million in 2023[270]. - Total sales growth for the year ended December 31, 2024 decreased by 3.2% compared to 2023, with core sales growth down by 2.6%[291]. Employee Engagement and Diversity - In 2024, the company achieved a 94% participation rate in employee engagement surveys, with 72% of respondents feeling engaged at work[62]. - The company maintained 99% gender pay equity and 100% race/ethnicity pay equity in the U.S. as of February 2024[59]. - The company employs around 12,300 individuals, with approximately 3,000 in the U.S. and 9,300 outside the U.S.[57]. Research and Development - The company plans to continue significant investments in R&D to maintain its competitive position and enter new markets[55]. - The company is focusing on product development and innovation, particularly in the Implant-Based Tooth Replacement and Orthodontic Solutions businesses, to drive growth[251]. - Continued investment in the Spark clear aligner system has led to increased manufacturing capacity and market adoption, expected to provide growth opportunities[253]. Financial Performance - Gross profit margin decreased to 54.7% in 2024 from 56.1% in 2023, primarily due to unfavorable product mix and impairment of long-lived assets[273]. - SG&A expenses increased to $1,158.0 million in 2024, representing 46.1% of sales, up from 41.2% in 2023[274]. - Operating profit for the Specialty Products & Technologies segment was $89.9 million in 2024, down from $232.1 million in 2023, with an operating profit margin of 5.6%[284]. - Interest expense decreased to $46.4 million in 2024 from $63.4 million in 2023, attributed to higher returns on cash and lower variable rate borrowings[280]. - The effective tax rate for 2024 was (3.1)%, a significant change from (82.5)% in 2023, mainly due to larger nondeductible impairment charges[282]. Acquisitions and Investments - The company is evaluating potential investments and acquisitions to strategically fit or expand its portfolio into new business areas[94]. - The company acquired Osteogenics Biomedical Inc., Allotech LLC, and OBI Biologics, Inc. on July 5, 2022, enhancing its Specialty Products & Technologies segment[95]. - The acquisition of Carestream Dental's intraoral scanner business was completed on April 20, 2022, which is part of the Equipment & Consumables segment[96]. Regulatory Compliance - The company’s manufacturing operations are subject to extensive government regulations, including those from the FDA for medical devices[68]. - The company is subject to various healthcare laws, including the Federal Anti-Kickback Statute and HIPAA, which regulate fraud, abuse, and the privacy of health information[77][78]. - The company must comply with the General Data Protection Regulation (GDPR), which imposes fines of up to €20 million or 4% of total worldwide annual turnover for non-compliance[88]. - The Personal Information Protection Act (PIPL) in China carries maximum penalties of CNY 50 million or 5% of annual revenue for violations related to personal data processing[89]. Economic and Market Conditions - The company faces challenges from global economic conditions, including inflation and supply chain disruptions, which can affect dental procedure utilization rates[247]. - Third-party payors are increasingly reducing reimbursements for medical products, which could impact dentist usage and patient demand[82]. - Sales volume was negatively impacted by lower demand in Europe, China, and North America, partially offset by strong demand in Russia[272]. Cash Flow and Debt Management - Net cash provided by operating activities was $336.5 million in 2024, an increase from $275.7 million in 2023, attributed to improved working capital management[297]. - Net cash used in investing activities decreased to $54.6 million in 2024 from $62.4 million in 2023, mainly due to lower capital expenditures[299]. - Net cash used in financing activities was $103.7 million in 2024, compared to net cash provided of $118.9 million in 2023, primarily due to a $100.0 million repayment of the 2028 Term Loan[300]. - As of December 31, 2024, the company had $1,069.1 million in cash and cash equivalents, with $850.8 million held outside the United States[303]. - The company has the ability to incur an additional $750.0 million of indebtedness under its revolving credit facility as of December 31, 2024[302]. Impairments and Charges - Goodwill and intangible asset impairment for 2024 was $1,153.8 million, significantly higher than $258.3 million in 2023, driven by adverse macroeconomic factors[276]. - The company recorded a $960.5 million goodwill impairment charge due to the fair value of five out of eight reporting units not exceeding their carrying values[333]. - An impairment charge of $101.1 million was recorded for certain indefinite-lived trade names within the Specialty Products & Technologies segment as of June 28, 2024[334]. - An impairment of $92.2 million related to developed technology and customer relationships was recorded within the Equipment & Consumables segment as of June 28, 2024[338].

Envista Holdings Corporation (NVST) reported fourth-quarter 2024 adjusted earnings per share (EPS) of 24 cents, down 17.2% year over year. The bottom line surpassed the Zacks Consensus Estimate by 4.3%.Find the latest EPS estimates and surprises on Zacks Earnings Calendar.The adjustments include non-cash charges related to the amortization of acquisition-related and other intangible assets, restructuring costs and asset impairments, among others.The company’s GAAP EPS was 1 cent compared with the year-ago q ...

Financial Data and Key Metrics Changes - In Q4 2024, the company reported sales of $653 million, with core sales increasing by 2% after adjusting for currency impacts [23][24] - Adjusted EBITDA margin for Q4 was 13.9%, a decrease of 170 basis points year-over-year, while adjusted gross margin improved to 57.2%, up nearly 500 basis points [25][26] - Free cash flow for the full year reached $303 million, a 35% increase compared to 2023 [11][40] Business Line Data and Key Metrics Changes - The Specialty Products & Technologies segment saw a slight decline of 40 basis points in core revenue, with orthodontics impacted by a 50% decline in China due to VBP preparations [33][34] - The Equipment & Consumables segment experienced a 6.4% increase in core sales, driven by a low prior year comparable for dental consumables [37][38] - Spark continued to show strong growth, achieving double-digit growth in 2024, excluding the net impact from revenue deferral [15][24] Market Data and Key Metrics Changes - The global dental market was flat to slightly up, with implants growing low single-digits, while diagnostics declined mid single-digits [19][20] - The orthodontics market faced challenges, particularly in China, where brackets and wires saw a significant decline [20][21] - The consumables sector remained flat to slightly positive, with stable channel inventories and high service levels [21] Company Strategy and Development Direction - The company is focusing on three areas: growth, operations, and people, with investments aimed at high-margin businesses like Nobel Biocare [13][14] - A restructuring initiative is expected to generate approximately $20 million in annualized savings, supporting the share repurchase program of up to $250 million over the next two years [12][48] - The company aims to maintain core growth of 1% to 3% and an adjusted EBITDA margin of around 14% for 2025, with a new EPS guidance of $0.95 to $1.05 per share [11][44] Management's Comments on Operating Environment and Future Outlook - Management noted that while the dental market remains stable, there is no strong evidence of an uptick in demand, with macroeconomic uncertainties persisting [50][51] - The company expects the diagnostics market to improve slightly in 2025, but guidance assumes flat conditions compared to 2024 [95][96] - Management expressed confidence in the growth trajectory of the implant business, supported by recent investments and leadership changes [72][74] Other Important Information - The company has refreshed its leadership team and made significant investments in employee engagement and talent development [18] - The company is actively working on new product launches, including advancements in diagnostic equipment and the Spark platform [110][111] Q&A Session Summary Question: Can you talk about potential upside and risks to the 2025 guidance? - Management highlighted Spark's growth, implant business momentum, and potential recovery in diagnostics as areas for upside, while macro uncertainties and currency fluctuations pose risks [60][69] Question: What are the expectations for the implant business moving forward? - Management expressed optimism about the implant business, noting positive growth in Q4 and ongoing investments in commercialization and innovation [72][74] Question: How does the company view the diagnostics market? - The diagnostics business is expected to improve slightly, with management anticipating flat to low single-digit growth in 2025, driven by exiting unprofitable geographies [95][96] Question: What is the company's strategy regarding tariffs and supply chain? - The company maintains a flexible supply chain strategy to mitigate tariff impacts, sourcing materials locally and manufacturing across multiple regions [136][138] Question: Can you provide insights on Spark's profitability and its impact on margins? - Spark is projected to become profitable in the second half of 2025, with each point of margin improvement contributing to overall company performance [90][91]

Envista Fourth Quarter 2024 – Earnings Presentation February 5, 2024 Forward Looking Statements Certain statements included or incorporated by reference in this presentation are "forward-looking statements" within the meaning of the U.S. federal securities laws. All statements other than historical factual information are forward-looking statements, including without limitation statements regarding: projections of revenue, expenses, profit, profit margins, tax rates, tax provisions, cash flows, pension and ...

For the quarter ended December 2024, Envista (NVST) reported revenue of $652.9 million, up 1.1% over the same period last year. EPS came in at $0.24, compared to $0.29 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of $645.87 million, representing a surprise of +1.09%. The company delivered an EPS surprise of +4.35%, with the consensus EPS estimate being $0.23.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how th ...

Envista (NVST) came out with quarterly earnings of $0.24 per share, beating the Zacks Consensus Estimate of $0.23 per share. This compares to earnings of $0.29 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 4.35%. A quarter ago, it was expected that this maker of dental products would post earnings of $0.09 per share when it actually produced earnings of $0.12, delivering a surprise of 33.33%.Over the last four quarters, the ...

Financial Performance - Q4 2024 net income was $1 million, a significant improvement from a net loss of $217 million in Q4 2023[5] - Adjusted EBITDA for Q4 2024 was $91 million, with an adjusted EBITDA margin of 13.9%, consistent with expectations[8] - Sales for Q4 2024 reached $653 million, reflecting a core sales increase of 2.0% compared to Q4 2023[8] - Operating cash flow for Q4 2024 was $132 million, representing a 30% increase year-over-year, while free cash flow was $124 million, up 24%[8] - The company expects core sales growth of 1% to 3% and adjusted EBITDA margins of approximately 14% for the full year 2025[9] - Adjusted earnings per share for 2025 are projected to range between $0.95 and $1.05[9] - The company reported a gross profit of $372.5 million for Q4 2024, compared to $335.9 million in Q4 2023[15] - Adjusted net income for the year ended December 31, 2024, was $126.5 million, down from $269.2 million in 2023[23] - Gross profit for the year ended December 31, 2024, was $1,372.7 million, a decrease of 4.7% from $1,440.5 million in 2023[23] - Adjusted EBITDA for the year ended December 31, 2024, was $296.1 million, down from $464.2 million in 2023[23] Cash Flow and Assets - The ending balance of cash and cash equivalents increased to $1,069.1 million in 2024 from $940.0 million in 2023[21] - Operating cash flow increased to $336.5 million in 2024 from $275.7 million in 2023, representing a 22% increase[20] - Free Cash Flow for the three months ended December 31, 2024, was $123.9 million, an increase from $99.9 million in the same period of 2023[33] - Total assets decreased to $5.35 billion as of December 31, 2024, down from $6.61 billion a year earlier[18] Segment Performance - Specialty Products & Technologies segment reported sales of $1,616.4 million for the year, down 1.6% from $1,642.4 million in 2023[25] - Equipment & Consumables segment sales decreased to $894.2 million in 2024 from $924.1 million in 2023, a decline of 3.2%[25] - Adjusted Operating Profit for the Equipment & Consumables segment for the three months ended December 31, 2024, was $60.9 million, an increase from $44.7 million in the same period of 2023, reflecting a growth of 36.2%[27] Losses and Equity - Net loss for the year ended December 31, 2024, was $1,118.6 million compared to a loss of $100.2 million in 2023[20] - The company reported an operating loss of $1,038.2 million for the year ended December 31, 2024, compared to a profit of $31.5 million in 2023[23] - The company’s total stockholders' equity was $2.93 billion as of December 31, 2024, compared to $4.17 billion at the end of 2023[18] - The company reported a net loss of $1.2 million for the three months ended December 31, 2024, compared to a net loss of $217.4 million in the same period of 2023[28] Adjusted Metrics and Non-GAAP Measures - Adjusted EBITDA is used as a supplemental measure for assessing operating performance, excluding interest, taxes, depreciation, amortization, and unusual losses or gains, to provide a clearer view of operational factors[37] - Free Cash Flow (FCF) is utilized to evaluate the company's ability to generate cash for business growth and acquisitions, although it does not account for debt service requirements[39] - Adjusted Diluted Shares Outstanding includes the dilutive impact of stock options and performance stock units, reflecting the adjusted net income compared to a net loss under GAAP[39] - The company excludes amortization of acquisition-related intangible assets from non-GAAP measures to facilitate consistent comparisons of operating results over time[39] - Core sales exclude the effects of acquisitions, divested product lines, discontinued products, and currency translation to provide a clearer view of ongoing operations[39] - Adjusted Gross Profit, Adjusted Operating Profit, and Adjusted Net Income are assessed to understand long-term profitability trends and compare performance with peers[37] - Management uses non-GAAP measures to evaluate the company's operating and financial performance, providing insights into underlying business trends[38] - The adjustments made in the financial reporting are aimed at obscuring underlying business trends and making long-term performance comparisons more challenging[39] Quarterly Performance - Adjusted Operating Profit for the three months ended December 31, 2024, was $81.5 million, compared to $89.6 million for the same period in 2023, representing a decrease of 1.1%[27] - Adjusted Net Income for the three months ended December 31, 2024, was $41.1 million, down from $49.7 million in the same period of 2023, reflecting a decline of 17.5%[28] - Adjusted Diluted Earnings Per Share for the three months ended December 31, 2024, was $0.24, compared to $0.29 for the same period in 2023, a decrease of 17.2%[29] - Total sales growth for the three months ended December 31, 2024, was 1.1%, while core sales growth was 2.0%[32] - Adjusted EBITDA for the three months ended December 31, 2024, was $91.0 million, down from $100.5 million in the same period of 2023, a decrease of 14.1%[31] - Adjusted Operating Profit as a percentage of sales for the three months ended December 31, 2024, was 12.5%, compared to 13.9% for the same period in 2023[27] - The average common stock shares outstanding - diluted for the three months ended December 31, 2024, was 173.7 million, slightly up from 173.5 million in the same period of 2023[30]